Covidien (NYSE:COV) to Sell Confluent Surgical Product Line to Integra LifeSciences (Nasdaq:IART)

Covidien plc (NYSE:COV) reported that it has entered into a definitive agreement with Integra LifeSciences Holdings Corp. (Nasdaq:IART) to sell its Confluent Surgical product line.

Under the terms of the agreement, COV will receive an initial cash payment of $235 million from IART upon the closing of the transaction. Additionally, COV may receive up to $30 million, contingent upon the achievement of certain performance measures related to the transition of the Confluent Surgical business to IART.

COV is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. COV manufactures, distributes and services a diverse range of industry-leading products in medical devices and supplies.

More about Integra LifeSciences Holdings Corp. (Nasdaq:IART) at www.covidien.com

***

Read full disclaimer at www.mikezaman.com/disclaimer